A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Trial Profile

A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms EXAMINER
  • Sponsors Exelixis
  • Most Recent Events

    • 25 Jan 2018 Planned End Date changed from 1 Mar 2018 to 31 Mar 2019.
    • 25 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2018.
    • 27 Mar 2015 New source identified and integrated (European Clinical Trials Database record:2013-003402-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top